• 100mg & 200mg tablets 

• 50mg in 5ml suspension is also approved  unlicensed

• 150mg/3ml & 300mg/10ml injection 

NHS England (June 2019) advises that prescribers should not initiate amiodarone in primary care for any new patient.

in exceptional circumstances, where there is a clinical need for amiodarone to be prescribed, this should be undertaken in a cooperation arrangement with a multi-disciplinary team and/or other healthcare professional. Amiodarone has an important place in the treatment of severe cardiac rhythm disorders where other treatments either cannot be used or have failed. It has potential major toxicity and its use requires monitoring both clinically and via laboratory testing. 

MHRA Drug Safety Update (Mar 2022): Amiodarone (Cordarone X): reminder of risks of treatment and need for patient monitoring and supervision

• 50mg & 100mg tablets
• 5mg in 1ml liquid unlicensed. 

• Approved for patients who are unsuitable for or not tolerant of amiodarone. Treatment should be initiated by a cardiologist.

• Injection: 150ml/15ml 

• unlicensed


• ECG monitoring is required to be carried out by as part of the initiation process of mexiletine.

• For use as a diagnostic test of Brugada syndrome.